{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39","upperLimit":"66","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as time from start of protocol treatment to disease relapse/progression, death or last contact, whichever occurs first. Progression-free survival was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.","dispersionType":"95% Confidence Interval","groups":[{"description":"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.\n\nTRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure.\n\nclofarabine: Given IV\n\nmelphalan: Given IV\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\ntacrolimus: Given IV or PO\n\nsirolimus: Given PO\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Treatment (Clofarabine, Melphalan, Transplant)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From start of protocol treatment to death due to any cause, disease relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years.","title":"Progression-free Survival at 2 Years","type":"PRIMARY","unitOfMeasure":"percent probability"}